☰

Susan K. Rathe, Ph.D. - Publications

Affiliations: 
2013 Microbiology, Immunology and Cancer Biology University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Oncology, Cell Biology, Bioinformatics Biology
Tree Info Similar researchers PubMed Report error

41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kurata M, Antony ML, Noble-Orcutt KE, Rathe SK, Lee Y, Furuno H, Ishibashi S, Ikeda M, Yamamoto K, Kitagawa M, Largaespada DA, Sachs Z. Proliferation and self-renewal are differentially sensitive NRASG12V oncogene levels in an acute myeloid leukemia cell line. Molecular Cancer Research : McR. PMID 35900472 DOI: 10.1158/1541-7786.MCR-22-0109  0.518
2021 Vélez-Reyes GL, Koes N, Ryu JH, Kaufmann G, Berner M, Weg MT, Wolf NK, Rathe SK, Ratner N, Moriarity BS, Largaespada DA. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 13. PMID 33808166 DOI: 10.3390/cancers13071584  0.747
2020 Conboy CB, Vélez-Reyes GL, Rathe SK, Abrahante JE, Temiz NA, Burns MB, Harris RS, Starr TK, Largaespada DA. R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers. Dna and Cell Biology. PMID 33320737 DOI: 10.1089/dna.2020.5585  0.533
2020 Smeester BA, Draper GM, Slipek NJ, Larsson AT, Stratton N, Pomeroy EJ, Becklin KL, Yamamoto K, Williams KB, Laoharawee K, Peterson JJ, Abrahante JE, Rathe SK, Mills LJ, Crosby MR, et al. Implication of ZNF217 in accelerating tumor development and therapeutically targeting ZNF217-induced PI3K-AKT signaling for the treatment of metastatic osteosarcoma. Molecular Cancer Therapeutics. PMID 32999043 DOI: 10.1158/1535-7163.MCT-20-0369  0.786
2020 Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, et al. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. Bone. 115353. PMID 32251854 DOI: 10.1016/J.Bone.2020.115353  0.793
2020 Kurata M, Antony ML, Noble KE, Rathe SK, Hirakouchi H, Yamamoto K, Kitagawa M, Sachs Z, Largaespada DA. Abstract 2582: Dose-dependent NRASG12V-mediated signaling controls cell cycle progression and leukemogenic signaling in a CRISPR/Cas9-modified human AML cell line Immunology. 80: 2582-2582. DOI: 10.1158/1538-7445.Am2020-2582  0.617
2019 Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. CD200 Checkpoint Reversal:A Novel Approach to Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31624103 DOI: 10.1158/1078-0432.Ccr-19-2234  0.539
2019 Rathe SK, Popescu FE, Johnson JE, Watson AL, Marko TA, Moriarity BS, Ohlfest JR, Largaespada DA. Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. Scientific Reports. 9: 358. PMID 30674975 DOI: 10.1038/S41598-018-36840-Z  0.761
2019 Moertel C, Pluhar GE, Ampudia-Mesias E, Xiong Z, Pennell CA, Rathe SK, Largaespada DA, Olin MR. IMMU-23. TARGETING THE CD200 CHECKPOINT TO ENHANCE IMMUNOTHERAPY FOR CNS TUMORS Neuro-Oncology. 21: ii97-ii98. DOI: 10.1093/Neuonc/Noz036.142  0.518
2018 Rahrmann EP, Wolf NK, Otto GM, Heltemes Harris L, Ramsey LB, Shu J, LaRue RS, Linden MA, Rathe SK, Starr TK, Farrar MA, Moriarity BS, Largaespada DA. Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma. Molecular Cancer Research : McR. PMID 30355676 DOI: 10.1158/1541-7786.Mcr-18-0582  0.783
2018 Scott M, Temiz N, Sarver A, LaRue R, Rathe S, Varshney J, Wolf N, Moriarity B, Obrien T, Spector L, Largaespada D, Modiano J, Subramanian S, Sarver A. Abstract PR14: Immune cell transcript levels, metastatic progression, and survival in osteosarcoma: A comparative transcriptome analysis Omics a Journal of Integrative Biology. 24. DOI: 10.1158/1557-3265.Sarcomas17-Pr14  0.74
2018 Camilleri ET, Beckmann PJ, Larson JD, Kurata M, Shu J, Pope E, Hudson WA, Temiz NA, Rathe SK, LaRue RS, Sarver AE, Scott MC, Varshney J, Modiano JF, Moriarity BS, et al. Abstract 2264: RNA sequencing based analysis of transposon-induced tumors reveals novel insights into cancer pathogenesis and progression Cancer Research. 78: 2264-2264. DOI: 10.1158/1538-7445.Am2018-2264  0.791
2018 Olin M, Ampudia-Mesias E, Pennell CA, Xiong Z, Rathe SK, Largaespada DA, Moertel CL, Pluhar GE. CADD-14. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 20: vi278-vi279. DOI: 10.1093/Neuonc/Noy148.1159  0.514
2017 Paul JA, Aich A, Abrahante JE, Wang Y, LaRue RS, Rathe SK, Kalland K, Mittal A, Jha R, Peng F, Largaespada DA, Bagchi A, Gupta K. Transcriptomic analysis of gene signatures associated with sickle pain. Scientific Data. 4: 170051. PMID 29292796 DOI: 10.1038/Sdata.2017.51  0.507
2017 Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector LG, Largaespada DA, Modiano JF, Subramanian S, Sarver AL. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression and survival in osteosarcoma. Cancer Research. PMID 29066513 DOI: 10.1158/0008-5472.Can-17-0576  0.737
2017 Largaespada DA, Rathe SK, Gupta K, Wang Y, Jha R, Aich A, Paul J, Abrahante JE, LaRue RS, Kalland K, Mittal A, Peng F, Bagchi A. Data from Transcriptomic analysis of gene signatures associated with sickle pain Scientific Data. 4: 170051. DOI: 10.6084/M9.Figshare.C.3491244.V1  0.501
2017 Williams KB, Williams RL, Rathe SK, Hawkinson J, Largaespada DA. Abstract A37: Synthetic lethality as a tool to reveal novel vulnerabilities in NF1-associated tumorigenesis Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A37  0.622
2016 Marko TA, Shamsan GA, Edwards EN, Hazelton PE, Rathe SK, Cornax I, Overn PR, Varshney J, Diessner BJ, Moriarity BS, O'Sullivan MG, Odde DJ, Largaespada DA. Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma. Scientific Reports. 6: 39059. PMID 27966608 DOI: 10.1038/Srep39059  0.748
2016 Kurata M, Rathe SK, Bailey NJ, Aumann NK, Jones JM, Veldhuijzen GW, Moriarity BS, Largaespada DA. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Scientific Reports. 6: 36199. PMID 27808171 DOI: 10.1038/Srep36199  0.714
2015 Kempema AM, Widen JC, Hexum JK, Andrews TE, Wang D, Rathe SK, Meece FA, Noble KE, Sachs Z, Largaespada DA, Harki DA. Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues. Bioorganic & Medicinal Chemistry. 23: 4737-45. PMID 26088334 DOI: 10.1016/J.Bmc.2015.05.037  0.577
2015 Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, Choi K, Holly KJ, Sarver AL, Scott MC, Forster CL, et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nature Genetics. 47: 615-24. PMID 25961939 DOI: 10.1038/Ng.3293  0.78
2015 Sachs Z, LaRue RS, Noble K, Rathe SK, Sarver AL, Ha NA, Largaespada DA. Abstract B34: Single cell RNA sequencing identifies the NRASG12V-mediated AML self-renewal signature. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B34  0.627
2015 Eckfeldt CE, Lee RD, Pomeroy EJ, Temiz AN, Rathe SK, Ma J, Gruber TA, Diaz-Flores E, Downing JR, Shannon KM, Largaespada DA. Abstract B01: Mechanisms of treatment resistance following Ras targeted therapy in acute myeloid leukemia. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B01  0.617
2014 Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood. 124: 3274-83. PMID 25316678 DOI: 10.1182/Blood-2013-08-521708  0.627
2014 Rathe SK, Moriarity BS, Stoltenberg CB, Kurata M, Aumann NK, Rahrmann EP, Bailey NJ, Melrose EG, Beckmann DA, Liska CR, Largaespada DA. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia. Scientific Reports. 4: 6048. PMID 25116387 DOI: 10.1038/Srep06048  0.776
2014 Sachs Z, LaRue RS, Nguyen HT, Sachs K, Hassan NAM, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. Abstract B15: NRASG12V oncogene mediates self-renewal in a murine model of acute myelogenous leukemia Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B15  0.635
2013 Rathe SK, Johnson JE, Silverstein KA, Erdmann JJ, Watson AL, Popescu FE, Ohlfest JR, Largaespada DA. MMuFLR: missense mutation and frameshift location reporter. Bioinformatics (Oxford, England). 29: 2353-4. PMID 23825368 DOI: 10.1093/Bioinformatics/Btt385  0.696
2013 LaRue RS, Nguyen H, Sachs K, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AG, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon K, Sachs Z, Largaespada DA. Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia Blood. 122: 819-819. DOI: 10.1182/Blood.V122.21.819.819  0.627
2012 Sachs Z, Nguyen H, Hassan NAM, Rathe SK, Sachs K, Diaz-Flores E, Bendall SC, Diers MD, Nolan GP, Shannon KM, Largaespada DA. Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature Blood. 120: 5116-5116. DOI: 10.1182/Blood.V120.21.5116.5116  0.625
2012 Sachs Z, Rathe SK, Diaz-Flores E, Diers MD, Shannon K, Largaespada DA. Abstract 4176: Activated NRAS mediates self-renewal capacity in AML Cancer Research. 72: 4176-4176. DOI: 10.1158/1538-7445.Am2012-4176  0.607
2011 Sachs Z, Rathe SK, Diaz-Flores E, Diers MD, Shannon KM, Largaespada DA. Delineating Critical Effectors of Remission Induction in a Mouse Model of AML Blood. 118: 5232-5232. DOI: 10.1182/Blood.V118.21.5232.5232  0.643
2011 Eckfeldt CE, Diaz-Flores E, Diers MD, Rathe SK, Shannon KM, Largaespada DA. Mechanisms of Relapse Following Targeted Therapy in An NRASG12V and Mll-AF9 Driven Mouse Model of AML Blood. 118: 2620-2620. DOI: 10.1182/Blood.V118.21.2620.2620  0.638
2011 Rathe SK, Stoltenberg CB, Largaespada DA. RNA-Sequencing of the Transcriptome of Ara-C Resistant Murine AML Cell Lines Identifies Potential Drug Targets Blood. 118: 2489-2489. DOI: 10.1182/Blood.V118.21.2489.2489  0.585
2010 Yin B, Tsai ML, Hasz DE, Rathe SK, LeBeau M, Largaespada DA. A microarray study of altered gene expression in Ara-C resistance in acute myeloid leukemia Leukemia. 24: 1543-1543. PMID 20703210 DOI: 10.1038/Leu.2010.59  0.57
2010 Rathe SK, Largaespada DA. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines. Leukemia. 24: 1513-5. PMID 20508618 DOI: 10.1038/Leu.2010.88  0.553
2010 Sachs Z, Diaz-Flores E, Diers MD, Sachs K, Bendall SC, Fienberg HG, Rathe SK, Nolan GP, Shannon K, Largaespada D. Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations Blood. 116: 3160-3160. DOI: 10.1182/Blood.V116.21.3160.3160  0.623
2010 Rathe SK, Largaespada D. A Screen for Drugs Showing Specific Co-Resistance or Hyper-Sensitivity Upon the Acquisition of Ara-C Resistance In AML Blood. 116: 1844-1844. DOI: 10.1182/Blood.V116.21.1844.1844  0.57
2008 Rathe SK, Largaespada D. A Novel Microarray Gene Expression Analysis of Murine AML Cell Lines Provides Clues to the Development of Drug Resistance to Ara-C Blood. 112: 5017-5017. DOI: 10.1182/Blood.V112.11.5017.5017  0.596
2008 Kim W, Rathe SK, Diers MD, Largaespada DA. A Murine AML Model for the Development of Resistance to NRAS(G12V) Oncogene Repression and/or Ara-C Treatment in Vivo Blood. 112: 4030-4030. DOI: 10.1182/Blood.V112.11.4030.4030  0.588
2007 Yin B, Tsai ML, Hasz DE, Rathe SK, Le Beau MM, Largaespada DA. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia. 21: 1093-7. PMID 17301810 DOI: 10.1038/Sj.Leu.2404595  0.565
2006 Yin B, Diers MD, Rathe SK, Lowe SW, Largaespada DA. Genetic Mechanisms of Cytarabine Resistance in Leukemia: Cell Culture and Mouse Transplantation Models. Blood. 108: 4374-4374. DOI: 10.1182/Blood.V108.11.4374.4374  0.628
Show low-probability matches.